8.30
-1.19%
Close of 19 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
Price performance
Chart by TradingView, with its own licensed prices
- Market value
- $66.1m
- Last close × shares
- Volume
- 153k
- Shares, 19 Nov 2026
About Biodesix
From its filings with the US Securities and Exchange Commission
Biodesix is based in Louisville, Colorado and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker BDSX. The SEC classifies its business as medical laboratories. In the fiscal year to 31 December 2025, it reported revenue of $88.5m and a net loss of $35.3m. At that date it held total assets of $87.5m and shareholders' equity of −$2.5m. By business, Diagnostic tests. brought in 89.5% of revenue, followed by Development Services [Member] at 10.5%.
Biodesix, Inc. (“Biodesix”, “we,” “us,” “our” or the “Company”) is a leading diagnostic solutions company. Our mission at Biodesix is to transform patient care and improve outcomes through personalized diagnostics that are timely, accessible, and address immediate clinical needs. We envision a world where patient disease is conquered through the guidance of personalized diagnostics.
We derive our revenue from two sources: (i) Biodesix Lung Diagnostic Testing (Lung Diagnostic Testing), providing lung diagnostic testing services for healthcare providers associated with our five blood-based tests and (ii) Biodesix Development Services (Development Services) providing diagnostic testing services and consulting to biopharmaceutical, life sciences, and diagnostic companies.
At Biodesix, we have built a team with deep experience in diagnostics including commercialization, reimbursement, regulatory, medical affairs, research and development, technology, and operations to provide needed products and services to address critical clinical questions and help improve patient care. We believe that establishing a new standard of care utilizing personalized diagnostics requires an extensive understanding of clinical needs, scientific expertise to develop tests using the optimal technology for each clinical question, development of clinical evidence to demonstrate benefits of the testing, a scalable operational infrastructure, and an established commercial channel to drive market adoption and payer coverage.
Quoted from its 10-K, filed 26 Feb 2026. Read the filing on SEC.gov ↗
How it makes its money
Revenue, year to 31 Dec 2025
- Diagnostic tests. $79.2m · 89.5%
- Development Services [Member] $9.3m · 10.5%
Latest on Biodesix
Our reporting
Next results
Due on 25 Feb 2027. Analysts expect earnings of -0.70 a share.
Other Health Care listings
Scenario calculator
Try your own numbers. This is arithmetic, not a forecast.
Gain or loss
Return
Leaves out fees, taxes and financing.
Frequently asked questions
What is Biodesix's ticker?
Biodesix trades as BDSX on its US listing, under ISIN US09075X2071.
What was Biodesix's last closing price?
8.30 on 19 Nov 2026. The figure is in USD and is never converted.
Sources and methodology
- Chart
- TradingView
- Close and company data
- SEC filings and our data supplier
- News
- Our reporting
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.